Selim Corm
Overview
Explore the profile of Selim Corm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al.
Nat Med
. 2024 Jun;
30(8):2235-2241.
PMID: 38830994
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of...
2.
Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, et al.
Haematologica
. 2023 Nov;
109(6):1857-1865.
PMID: 38031755
Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (rituximab, bendamustine, velcade and dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over...
3.
Crickx E, Ebbo M, Riviere E, Souchaud-Debouverie O, Terriou L, Audia S, et al.
Br J Haematol
. 2023 May;
202(4):883-889.
PMID: 37247631
Combining drugs could be an effective option for treating multirefractory ITP, that is, patients not responding to rituximab, thrombopoietin receptor agonists (TPO-RA) and splenectomy. We conducted a retrospective, multicenter, observational...
4.
Roupie A, Guedon A, Terrier B, Lahuna C, Jachiet V, Regent A, et al.
Semin Arthritis Rheum
. 2020 Sep;
50(5):879-884.
PMID: 32896704
Introduction: Our objective was to evaluate characteristics, treatment and outcome of vasculitis associated with myelodysplastic syndrome (MDS) and chronic myelomonicytic leukemia (CMML) PATIENTS AND METHODS: Retrospective descriptive analysis of MDS/CMML-related...
5.
Dony A, Belhabri A, Bertrand Y, Sebban C, Cony-Makhoul P, Sobh M, et al.
J Adolesc Young Adult Oncol
. 2019 Aug;
8(6):684-696.
PMID: 31411521
Management of adolescent and young adults (AYAs) cancer is very heterogeneous. In the case of lymphomas, outcomes are mostly favorable but there is still room for improvement. We retrospectively collected...
6.
Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, et al.
Haematologica
. 2018 Oct;
104(3):497-504.
PMID: 30287621
Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective...
7.
Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, et al.
Haematologica
. 2018 Sep;
104(1):138-146.
PMID: 30171024
We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older....
8.
Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, et al.
Haematologica
. 2017 Nov;
103(2):212-220.
PMID: 29170252
Few therapeutic options are available for patients with aplastic anemia who are ineligible for transplantation or refractory to immunosuppressive therapy. Eltrombopag was recently shown to produce trilineage responses in refractory...
9.
Boyer T, Grardel N, Copin M, Roumier C, Touzart A, Buchdahl A, et al.
Ann Hematol
. 2015 Jul;
94(10):1759-60.
PMID: 26152552
No abstract available.
10.
Mondet J, Park J, Menard A, Marzac C, Carillo S, Pourcelot E, et al.
Haematologica
. 2015 Feb;
100(5):e176-8.
PMID: 25661444
No abstract available.